Cytokine Release Syndrome Management Market Outlook: Strong Revenue and CAGR Growth Forecast Through 2029
Use Code ONLINE20 to Save 20% On Global Market Reports – Gain Access to Trusted Market Data, Growth Indicators, and Industry Analytics
How Has the Cytokine Release Syndrome Management Market Performed Historically, and What Are Its Future Growth Projections?
The cytokine release syndrome management market size has grown strongly in recent years. It will grow from $22.32 billion in 2024 to $23.76 billion in 2025 at a compound annual growth rate (CAGR) of 6.5%. The growth in the historic period can be attributed to rising healthcare expenditure, increasing awareness, changing lifestyle, high disposable income, adoption of personalized medicine approaches and increasing use of targeted therapies.
The cytokine release syndrome management market size is expected to see strong growth in the next few years. It will grow to " $30.48 billion in 2029 at a compound annual growth rate (CAGR) of 6.4%. The growth in the forecast period can be attributed to driving up demand for diagnostic tools and treatments, growing government funding, an increase in the demand for effective therapies, a rising geriatric population, and rising initiatives by public and private organizations. Major trends in the forecast period include minimally invasive breast biopsy devices, strategic partnerships and collaborations, home-based antibiotic infusion services, the emergence of novel drug delivery systems, and the integration of electronic health records in infection tracking.
Get your free report sample today:
What Are the Essential Drivers Propelling the Cytokine Release Syndrome Management Market Forward?
The increasing use of targeted therapies is expected to propel the growth of the cytokine release syndrome management market going forward. Targeted therapies are drugs or treatments designed to specifically block the growth and spread of cancer by interfering with molecular targets involved in tumor development. The increasing use of targeted therapies is primarily due to their ability to precisely target cancer cells while minimizing damage to healthy cells, improving treatment efficacy, and reducing side effects compared to traditional therapies. Cytokine release syndrome management is essential in optimizing targeted therapies by controlling intense inflammatory reactions, which enhances the safety and effectiveness of treatments such as CAR-T cell therapy and immune checkpoint inhibitors. For instance, in January 2024, according to the American Society of Gene and Cell Therapy, a US-based organization for gene and cell therapy, in the fourth quarter of 2023, the number of gene therapies in Phase III clinical trials increased by 10%, marking the first quarterly rise of this kind since the third quarter of 2022. Therefore, the increasing use of targeted therapies is driving the growth of the cytokine release syndrome management market.
What Are the Primary Market Segments in the Cytokine Release Syndrome Management Market?
The cytokine release syndrome managementmarket covered in this report is segmented –
1) By Treatment Type: Monoclonal Antibodies; Corticosteroids; Intravenous Immunoglobulin (IVIG); Targeted Therapy; Supportive Care; Other Treatment Types
2) By Indication: Chimeric Antigen Receptor (CAR) T-Cell Therapy; Immune Checkpoint Inhibitors; Hematopoietic Stem Cell Transplantation (HSCT); Autoimmune Diseases; Infections; Other Indications
3) By Route Of Administration: Intravenous (IV); Subcutaneous (SC); Oral; Intramuscular (IM); Intrathecal; Other Routes Of Administration
4) By End Users: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies; Specialty Clinics; Research Institutions; Other End Users
Subsegments:
1) By Monoclonal Antibodies: Tocilizumab; Siltuximab; Infliximab; Rituximab; Other Monoclonal Antibodies
2) By Corticosteroids: Dexamethasone; Prednisone; Methylprednisolone; Hydrocortisone; Other Corticosteroids
3) By Intravenous Immunoglobulin (IVIG): Immunoglobulin G (IgG)-Based Intravenous Immunoglobulin; Immunoglobulin A (IgA)-Based Intravenous Immunoglobulin; Immunoglobulin M (IgM)-Based Intravenous Immunoglobulin; Polyvalent Intravenous Immunoglobulin; Other Types of Intravenous Immunoglobulin
4) By Targeted Therapy: Janus Kinase (JAK) Inhibitors; Interleukin-6 (IL-6) Inhibitors; Tumor Necrosis Factor-Alpha (TNF-a) Inhibitors; Bruton's Tyrosine Kinase (BTK) Inhibitors; Other Targeted Agents
5) By Supportive Care: Antipyretic Medications; Analgesic Medications; Intravenous Fluids And Electrolyte Solutions; Oxygen Therapy; Vasopressor Agents
6) By Other Treatment Types: Plasmapheresis (Therapeutic Plasma Exchange); Antihistamine Medications; Leukapheresis; Experimental Therapies; Nutritional Support
Which Future-Ready Trends Are Expected to Influence the Cytokine Release Syndrome Management Market?
Major companies operating in the cytokine release syndrome management market are focusing on conducting clinical trials to develop innovative therapies, such as host-directed small molecule drugs, aimed at modulating the immune response and reducing the severity of cytokine storms without compromising the body’s ability to fight infections or cancer. A host-directed small molecule drug is a low molecular weight compound that targets the host’s immune signaling pathways to suppress excessive cytokine production, thereby helping manage cytokine release syndrome (CRS) by preventing immune system overactivation. For instance, in April 2025, CytoAgents Inc., a US-based biotechnology company, announced the successful completion of the first dose-escalation cohort in its Phase 1b/2a clinical trial of CTO1681, a host-directed small molecule drug developed to prevent and treat CRS in patients receiving CAR T-cell therapy. The investigational therapy demonstrated a favorable safety profile, with no dose-limiting toxicities or disruption to CAR T-cell efficacy. The trial, utilizing a rolling six dose-escalation design, is being conducted to assess the safety, tolerability, and preliminary efficacy of CTO1681, as well as to establish the recommended phase 2 dose.
Who Are the Top Performers and Innovators in the Cytokine Release Syndrome Management Market?
Major companies operating in the cytokine release syndrome management market are Pfizer Inc., Johnson & Johnson Private Limited, F. Hoffmann-La Roche Ltd., AbbVie Inc., Sanofi S.A., Bristol Myers Squibb Company, Novartis AG, GlaxoSmithKline plc, Amgen Inc., Gilead Sciences Inc., Regeneron Pharmaceuticals Inc., Genentech Inc., Incyte Corporation, Swedish Orphan Biovitrum AB, Biocon Limited, MacroGenics Inc., Legend Biotech Corporation, Bluebird Bio Inc., InflaRx N.V., Humanigen Inc.
Get the detailed cytokine release syndrome management market report today
Which Regional Markets Are Likely to See the Most Significant Expansion in the Coming Years?
North America was the largest region in the cytokine release syndrome management market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cytokine release syndrome management market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Contact Us:
The Business Research Company: https://thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email: info@tbrc.info
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Comments
Post a Comment